Your session is about to expire
← Back to Search
Ligation Device
Left Atrial Appendage Closure Device for Atrial Fibrillation (LASSO-AF Trial)
N/A
Waitlist Available
Led By Sheldon Singh, MD
Research Sponsored by Aegis Medical Innovations
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Documented non-valvular atrial fibrillation
Age >=18 years
Must not have
Cardiogenic shock or hemodynamic instability
Previous cardiac surgery involving opening of the pericardium
Timeline
Screening 3 weeks
Treatment Varies
Follow Up change between baseline to 6-months and 1-year from procedure
Awards & highlights
Summary
This trial is testing a new device called the Aegis Sierra Ligation System, which is used to close off a small part of the heart. It targets patients with a specific type of irregular heartbeat who are at high risk for stroke. The device works by making a small incision and sealing off the area to prevent blood clots.
Who is the study for?
This trial is for adults with non-valvular atrial fibrillation at risk of stroke, needing a non-drug alternative to oral anticoagulants. Candidates must be willing to consent and follow study procedures, able to take antiplatelet therapy post-procedure, and have a CHA2DS2-VASc score of ≥2. Exclusions include recent heart attack or surgery, certain heart conditions or diseases, life expectancy under 24 months, pregnancy, drug/alcohol addiction.
What is being tested?
The Aegis Sierra Ligation System is being tested on patients with atrial fibrillation to close off the left atrial appendage using a minimally invasive approach. The goal is safety and function assessment in up to 30 participants across Canada and the US.
What are the potential side effects?
Potential side effects may include complications from minimally invasive cardiac procedures such as bleeding or infection at the access site, allergic reactions (especially if sensitive to nickel), heart rhythm problems due to manipulation of the heart's structure.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have been diagnosed with a type of irregular heartbeat not related to heart valve issues.
Select...
I am 18 years old or older.
Select...
I can take medication to prevent blood clots after a surgical procedure.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I do not have a condition where my heart can't pump enough blood.
Select...
I have had heart surgery that involved opening the protective covering of the heart.
Select...
I have had radiation therapy to the chest area before.
Select...
I do not have severe liver, kidney, or lung disease.
Select...
I understand the study's purpose, importance, and procedures.
Select...
I cannot take blood thinners or anti-clotting medications.
Select...
I have a heart condition present from birth or abnormal connections in my heart or lungs.
Select...
I have severe heart failure symptoms.
Select...
I have right heart dysfunction or high blood pressure in my lungs.
Select...
I have a significant heart valve problem or a mechanical heart valve.
Select...
My condition involves a tumor in the heart.
Select...
I have symptoms or known issues with my carotid artery or aorta.
Select...
My heart's pumping ability is significantly reduced.
Select...
I have not had chemotherapy in the last 12 months.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ change between baseline to 6-months and 1-year from procedure
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change between baseline to 6-months and 1-year from procedure
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Number of participants free from the safety composite of device or procedure-related Major Adverse Events
Secondary study objectives
Number of participants that achieve Procedural Success
Number of participants that achieve Technical Success
Number of participants that achieve a residual flow ≤ 5mm distal to the closure site as measured by transesophageal echo (TEE)
+13 moreTrial Design
1Treatment groups
Experimental Treatment
Group I: Aegis Sierra Ligation SystemExperimental Treatment1 Intervention
The Aegis Sierra Ligation System is a series of devices designed for epicardial ligation of the Left Atrial Appendage through a minimally invasive transcatheter approach.
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for Atrial Fibrillation (AF) include pharmacological approaches like rate control medications (beta-blockers, calcium channel blockers) and rhythm control medications (antiarrhythmics), as well as anticoagulants to prevent stroke. Non-pharmacological treatments involve electrical cardioversion and catheter ablation.
The Aegis Sierra Ligation System, a mechanical ligation device, specifically targets the left atrial appendage (LAA) to prevent stroke by closing off this area where blood clots often form. This is significant for AF patients as it provides a minimally invasive method to reduce stroke risk, potentially eliminating the need for long-term anticoagulation therapy.
[Treatment of Patients With Atrial Fibrillation: the Search for Optimal Solutions].
[Treatment of Patients With Atrial Fibrillation: the Search for Optimal Solutions].
Find a Location
Who is running the clinical trial?
Aegis Medical InnovationsLead Sponsor
Applied Health Research CentreOTHER
22 Previous Clinical Trials
70,889 Total Patients Enrolled
2 Trials studying Atrial Fibrillation
308 Patients Enrolled for Atrial Fibrillation
Sheldon Singh, MDPrincipal InvestigatorSunnybrook Health Sciences Centre, Ontario Canada
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- Doctors think you have less than 2 years to live.I do not have a condition where my heart can't pump enough blood.I have not had a stroke or mini-stroke in the last 3 months.I have had heart surgery that involved opening the protective covering of the heart.Your echocardiogram or CT scan does not show a specific part of your heart called the left atrial appendage.I have been diagnosed with a type of irregular heartbeat not related to heart valve issues.You have a score of 2 or higher on the CHA2DS2-VASc assessment.You have had serious chest injury to the front of your chest in the past.You cannot undergo a transesophageal echocardiography (TEE) for health reasons.Your body part being studied doesn't look normal in the pictures taken by the doctors.You are allergic to nickel.You have certain health conditions that make it risky to access the area around your heart.I understand the study's purpose, importance, and procedures.I am 18 years old or older.I can take medication to prevent blood clots after a surgical procedure.I cannot take blood thinners or anti-clotting medications.I have a heart condition present from birth or abnormal connections in my heart or lungs.I have severe heart failure symptoms.I have right heart dysfunction or high blood pressure in my lungs.I have a significant heart valve problem or a mechanical heart valve.My condition involves a tumor in the heart.I have had radiation therapy to the chest area before.I have had pericarditis or issues related to the pericardium.I am currently on long-term steroid treatment, not just for breathing issues.I do not have severe liver, kidney, or lung disease.I have had a heart attack in the last 3 months.I have symptoms or known issues with my carotid artery or aorta.You have a blood clot in a specific part of your heart or it was seen on a special heart test within 48 hours before the procedure.My heart's pumping ability is significantly reduced.I have a valid reason to avoid blood thinner pills.I have not had chemotherapy in the last 12 months.
Research Study Groups:
This trial has the following groups:- Group 1: Aegis Sierra Ligation System
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Share this study with friends
Copy Link
Messenger